ArticleInvestigative ophthalmology & visual science2015
Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer.
Article in Investigative ophthalmology & visual science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Spotting the Diagnosis: A Case Report of Paraneoplastic Retinopathy Masquerading As White Dot Syndrome.Cureus · 2026Article
- Correlation of Anti-TULP1 Autoantibodies with Breast Cancer and Autoimmune Retinopathy.International journal of molecular sciences · 2025Article
- Clinical, electrophysiologic and serologic evidence of cancer associated retinopathy preceding a diagnosis of breast cancer.BMJ case reports · 2024Article
- Limited Clinical Value of Anti-Retinal Antibody Titers and Numbers in Autoimmune Retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Importance of Autoimmune Responses in Progression of Retinal Degeneration Initiated by Gene Mutations.Frontiers in medicine · 2021Review
- Ocular Paraneoplastic Syndromes.Biomedicines · 2020Review
- Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy.Clinical immunology (Orlando, Fla.) · 2020Article
- Cancer-associated Retinopathy Developing After 10 Years of Complete Breast Cancer Remission.Neuro-ophthalmology (Aeolus Press) · 2019Article
- Cancer-associated retinopathy after surgery for breast cancer: a case report and review of the literature.Surgical case reports · 2018Article
- [Arch-shaped retinal appearance of a previously healthy women].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Article
- Impact of Autoantibodies against Glycolytic Enzymes on Pathogenicity of Autoimmune Retinopathy and Other Autoimmune Disorders.Frontiers in immunology · 2017Review
- Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy.American journal of ophthalmology case reports · 2016Article
- Paraneoplastic neurological complications of breast cancer.Experimental hematology & oncology · 2015Review
- Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cancer-associated retinopathy (CAR) is an uncommon paraneoplastic disorder of the retina that is frequently associated with breast cancer in pre- and postmenopausal women older than 50 years. In this review, we will give an update on the current knowledge regarding the association of antiretinal autoantibodies with the breast-CAR syndrome. Women with breast cancer and visual indications of CAR have a significantly increased incidence of autoantibodies (AAbs) against retinal proteins when compared to healthy women. The onset of visual loss in association with antiretinal AAbs peaks 2 to 3 years after the clinical diagnosis of breast cancer. Differences in severity of symptoms between women with or without antiretinal AAbs are evident, revealing more unfavorable presentation in seropositive women. The incidence of CAR in breast cancer is likely to rise as the survival time of patients with breast cancer increases; consequently, a prediction of breast-CAR based on autoimmunity to individual retinal antigens, or to panels of antigens (signatures), is clinically important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.